APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
Germany and China Reaffirm Open Trade and Strategic Partnership in Landmark Beijing Visit 
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge 
Asian Stocks Tumble as US-Iran Conflict Escalates and Oil Prices Surge 
OpenAI Secures $110 Billion Funding Round at $840 Billion Valuation Ahead of IPO 
FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute 
Dominican Republic Unveils Massive Rare Earth Deposits to Boost High-Tech and Energy Sectors 
PBOC Scraps Forex Risk Reserve as Yuan Rally Pressures Chinese Exporters 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
Bank of Japan Signals Further Interest Rate Hikes as Inflation Trends Toward 2% Target 
Oil Prices Surge 13% as U.S.-Israel Strikes on Iran Spark Supply Fears 
Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology 
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling 
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
